Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GTXI
Now ONCT
I think they should issue calculators with the new shares. Geeeeez
GTXI
NO, I don't think some shorts were trapped, I think it is a prime opportunity for those who short stock to take advantage of the merger, and the low float to drive the stock up alot to over $25.00 or even higher, then short it back down to .... say $6.00 or less.
For the rest of us get in low and sell as close to the top as possible when the shorts drive it up.
JMO
You think some shorts were trapped? I dont think that RS here is a bad thing, company has a chance to drive pps to the moon here with such low float! Lets see
GTXI
Sounds about right. Perhaps a news release or another filing about Oncternals continued favorable results for their various trials in the works.
So many variables..
I agree. I do expect a gap up followed by continued rise, followed in the early afternoon by a small dip then leveling out. Just speculation.
GTXI
I sill don't see any mention of a share increase or an offering so with an 11.3M fl;oat and a 1:7 R/S should leave, if my amath is right, a float of 1,614,285... could go bonkers IMO. The only thing I could think of that could or would hinder a great trading day would be an offering posting or a share increase filed prior to the opening bell.
If that does not happen there should be a scramble for shares and the pps should move quickly.
Add to that the shorters that will want to drive the price up as high as possible. Whooooooa !!!. GLTA and will see what happens.
Each trader should do their own DD and make their own decisions.
Love to hear why a reverse split necessitated for the reverse merger is a bad thing.
Note: the usual suspects, staving off bankruptcy, prevention of delisting, theoretical uplisting shenanigans, etc, are not present here.
What we have is a symbiotic relationship.
Ooooops! I forgot to mention. My brokerage account has replaced the ticker GTXI with ONTC.
Thanks paps3. Here are 3 links. It appears that the merger was finalized on Friday, June 7, '19 and EDGAR notification should appear on Monday June 10th '19 since they don't post over the weekend.
Note; I wrote, "Appears". I can't guarantee that this information is accurate, or will be the effective date, but "if it looks like a duck, quacks, and has feathers..."
nasdaq trader
Adobe PDF
EDGAR
GTXI Can you provide a link for the information in your post?
I don"t see anything about it on TDA stock page nor on the EDGAR filings search.
DATE: SUBJECT:
JUNE 7, 2019
GTX, INC. ? REVERSE SPLIT AND NAME/SYMBOL/CUSIP CHANGE
OPTION SYMBOL: GTXI
NEW SYMBOL: ONCT1
DATE: 6/10/19
GTx, Inc. (GTXI) has announced a 1-for-7 reverse stock split and a name/symbol/CUSIP change. As a result of the reverse stock split and name/symbol/CUSIP change, each GTXI Common Share will be converted into the right to receive approximately 0.142857 (New) Oncternal Therapeutics, Inc. (ONCT) Common Shares. The reverse stock split and name/symbol/CUSIP change will become effective before the market open on June 10, 2019.
NOTE: GTx, Inc. has declared a dividend of one (1) non-transferable contingent value right (CVR) to shareholders of record on Friday, June 7, 2019. The GTXI option deliverable will NOT be adjusted to include the non-transferable CVR.
CONTRACT ADJUSTMENT
#45165
Effective Date: Option Symbol:
Contract Multiplier:
Strike Divisor: New Multiplier:
New Deliverable Per Contract:
CUSIP:
June 10, 2019
GTXI changes to ONCT1
1
1
100 (e.g., for premium or strike dollar extensions 1.00 will equal $100)
1) 14 (New) Oncternal Therapeutics, Inc. (ONCT) Common Shares 2) Cash in lieu of approximately 0.2857 fractional ONCT Shares
Note: The GTXI option deliverable will not be adjusted to include the non-transferable Contingent Value Right.
ONCT (New): 68236P107
PRICING
Until the cash in lieu amount is determined, the underlying price for ONCT1 will be determined as follows: ONCT1 = 0.142857 (ONCT)
DELAYED SETTLEMENT
The ONCT component of the ONCT1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the ONCT1 deliverable until the cash in lieu of fractional ONCT Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.
DISCLAIMER
This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).
The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.
ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.
For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.
Very easy to $10 all signs are there
that be awesome and it's a lot of beer money for me. hehehe...
Like someone gathering shares
Some strange trading, up aftermarket and now down premarket
good news, or???? Could send it to 2 Dollars? or ?
MERGER WENT THROUGH
Great news. Oncternal Therapeutics Update
Oncternal Therapeutics Announces Update
Thank you for great news
I haven't noticed any news lately, can you post a link?
5 Dollar is possible
Isnt this news solid enough to send it higher
Movin' on up...gotta love it.
Gtxi exploding on good results here.... Hild tight 10 Dollars easily an merger coming soon
New base at $1.07 1st resistance @ $1.27
I agree that once the "Ambulance chasers" get involved, PPS often goes up. Frequently, however it is because of their involvement, rather than in spite of it.
Mr. Hanover explained that the complexity of trying to merge GTx’s SARD technology with Company D’s SERD program under the umbrella of a holding company controlled by Company D would make it difficult for GTx shareholders to have any liquidity in this investment and the equity split being suggested for GTx shareholders was inadequate. Dr. Wills reported that discussions with Company L continued to be positive but their proposed equity split for a combined company (which was 90% for Company L’s stockholders and 10% for GTx’s stockholders) was, in his opinion, insufficient and there was little synergy in Company L’s technology and what GTx would be bringing to the combined company for development.
The original agreement was a bad deal for shareholders.
Crazy volume too last few days....
this can explode to 10 till 20 Dollar EASILY !!!! any opinions???
Here we go shareholders deserve reward after holding for good action from GTXI.
News about the merger has landed.
another ambulance chasing law firm just jumped on the pile @7:07 pm......investigating the merger of bpi...coty...ctl...GTXI...hf...nite......monteverde & associates........hahahahahahahahahahahahahahah.......these actions never go anywhere, and I strongly believe when all the n y law firms jump in, it is an attempt to drive down price....someone wants to accumulate (big news coming ??)these law firms are in bed with brokers and mm`s......it`s all a rigged game..........I usually increase my position, when these lawyers show up.........it has served me well many times in the past!!
BUY...BUY...BUY...BUY...BUY...BUY...$$$$$$...GTXI $$$$..GLTA..jmho
Hopefully some news about the merger soon
GTXI Perhaps the S-4 will be filed before pre-mkt on Monday. Cant think of anything else that is do..however, a share holder update would really be nice. GLTA
Was hoping that there would be an update on the merger by now...
Just checking if anyone was awake here. 10% rise triggered an alert on my stuff. (I hate the word, "Portfolio").
Time to do a little research.
We know it for days. Any new news today?
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement
Website for Oncternal Therapeutics:
http://www.oncternal.com/investors-media/news
I agree! GTXi had to do something. I don't see those in the best position to make that RM decision, screwing themselves. But when it comes down to voting to approve it, we will see how it goes down. In the meantime, I'm going to buy/sell shares as the opportunity arises!
All IMO. GLTA & GTXI!
Was questioning everything, then listened to replay of CC. Still needing a little clarity, never been through a reverse merger like this, but liking what I see with the future ONCT, much better than I like the destination of GTXI without them.
Followers
|
69
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1461
|
Created
|
02/25/08
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=GTXI
Charts and tec stuff
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules
to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions in the United States. The
company markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale
drug distributors. Its product candidates in clinical development include ACAPODENE, a selective estrogen receptor modulator,
which is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy, for
advanced prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called
high grade prostatic intraepithelial neoplasia (PIN). The company also develops Ostarine, a selective androgen receptor modulator,
which is in phase IIb clinical trials for the treatment of cancer cachexia; and for chronic kidney disease, and end-stage renal disease.
In addition, GTx develops Andarine for the treatment of various medical conditions relating to muscle wasting and/or bone loss;
prostarine for the treatment of benign prostatic hyperplasia; and andromustine, an anticancer product candidate for hormone refractory
prostate cancer. It has collaborations with Hybritech, Inc.; diaDexus, Inc.; MacroArray Technologies, LLC; Onconome, Inc.; and
Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN. GTx also has a research and development,
and strategic collaboration with Merck & Co., Inc. for the development of selective androgen receptor modulators. The company was
founded in 1997 and is headquartered in Memphis, Tennessee.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |